V
Varsha K. Jain
Researcher at GlaxoSmithKline
Publications - 24
Citations - 860
Varsha K. Jain is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Vaccination & Reactogenicity. The author has an hindex of 15, co-authored 24 publications receiving 786 citations.
Papers
More filters
Journal ArticleDOI
Vaccine for Prevention of Mild and Moderate-to-Severe Influenza in Children
Varsha K. Jain,Luis Rivera,Khalequ Zaman,Roberto A. Espos,Chukiat Sirivichayakul,Beatriz P. Quiambao,Doris Maribel Rivera-Medina,Pirunghul Kerdpanich,Mehmet Ceyhan,Ener Cagri Dinleyici,Alejandro Cravioto,Mohammed Yunus,Pornthep Chanthavanich,Kriengsak Limkittikul,Zafer Kurugöl,Emre Alhan,Adrian Caplanusi,Serge Durviaux,Philippe Boutet,Opokua Ofori-Anyinam,Vijayalakshmi Chandrasekaran,Ghassan Dbaibo,Bruce L. Innis +22 more
TL;DR: The QIV was efficacious in preventing influenza in children and associated with reduced risks of a body temperature above 39°C and lower respiratory tract illness, as compared with the control vaccine, in the per-protocol cohort.
Journal ArticleDOI
A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 years
Joseph B. Domachowske,Heidemarie Pankow-Culot,Milagros Bautista,Yang Feng,Carine Claeys,Mathieu Peeters,Bruce L. Innis,Varsha K. Jain +7 more
TL;DR: QIV vs TIV showed superior immunogenicity for the additional B strain without interfering with immune responses to shared strains, suggesting QIV may offer improved protection against influenza B in children compared with current trivalent vaccines.
Journal ArticleDOI
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years
Dorothee Kieninger,Eric Sheldon,Wen-Yuan Lin,Chong-Jen Yu,José M. Bayas,Julian J. Gabor,Meral Esen,Jose Luis Fernandez Roure,Silvia Narejos Perez,C. Sanchez,Yang Feng,Carine Claeys,Mathieu Peeters,Bruce L. Innis,Varsha K. Jain +14 more
TL;DR: QIV provided superior immunogenicity for the additional B strain compared with TIV, without interfering with antibody responses to the three shared antigens, suggesting that the candidate QIV is a viable alternative to TIV for use in adults, and could potentially improve protection against influenza B.
Journal ArticleDOI
Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example
Jiří Beran,Veronika Wertzova,Karel Honegr,Eva Kaliskova,Martina Havlíčková,Jiří Havlík,Helena Jirincova,Pascale Van Belle,Varsha K. Jain,Bruce L. Innis,Jeanne-Marie Devaster +10 more
TL;DR: The atypical nature of the influenza season during this study was unable to assess TIV efficacy, illustrating the challenge of conducting a prospective influenza vaccine efficacy trial during a single season when influenza attack rates and drift in circulating strains or B virus lineage match can be difficult to estimate in advance.
Journal ArticleDOI
Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: A phase III, randomized trial
Juan Carlos Tinoco,Noris Pavía-Ruz,Aurelio Cruz-Valdez,Carlos Aranza Doniz,Vijayalakshmi Chandrasekaran,Walthère Dewé,Aixue Liu,Bruce L. Innis,Varsha K. Jain +8 more
TL;DR: Immunogenicity of QIV lots was consistent, QIV was superior to TIV for the alternate B-lineage strain, andQIV was non-inferior versus TIVs for shared strains (A/H1N1, A/H3N2, B-strain).